Atea Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax
Atea Pharmaceuticals, Inc. (AVIR) reported Other Comprehensive Income (Loss), Net of Tax of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $1.00K.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$271.00K.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $201.00K, a 78.18% decline year-over-year.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$81.00K.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$59.00K, a 326.92% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $26.00K, a 97.08% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $891.00K.
- Atea Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$684.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-12 | -$270.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$271.00K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | -$59.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $201.00K 10-Q · filed 2025-11-12 | $120.00K derived: sum of 2 quarters · filed 2026-08-12 | $5.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$81.00K 10-Q · filed 2026-08-12 | -$196.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$115.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $26.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $921.00K 10-Q · filed 2025-11-12 | $822.00K derived: sum of 2 quarters · filed 2025-11-12 | $434.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$99.00K 10-Q · filed 2025-11-12 | -$487.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | -$388.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $891.00K 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $48.00K 10-Q · filed 2024-11-07 | $45.00K derived: sum of 2 quarters · filed 2024-11-07 | $422.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$3.00K 10-Q · filed 2024-11-07 | $374.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $377.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$684.00K 10-K · filed 2024-02-28 | |||
| 2022-09-30 | -$855.00K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |